NasdaqGS:ABCLLife Sciences
A Look At AbCellera Biologics (ABCL) Valuation After New Optimistic Coverage From Jones Trading
Jones Trading has initiated coverage on AbCellera Biologics (ABCL) with an optimistic view, drawing fresh attention to the antibody drug developer and prompting investors to reassess the stock’s risks, pipeline, and recent share performance.
See our latest analysis for AbCellera Biologics.
At a share price of US$3.54, AbCellera Biologics has seen a 2.91% 1 day share price return and a 90 day share price return decline of 18.99%, while the 1 year total shareholder return of 47.5% contrasts...